Medicine & Health25 February 2026
Testing Ayurvedic medicine for COVID-19: A Rigorous Look at the Latest Clinical Data
Source PublicationJournal of Investigative Medicine
Primary AuthorsPatsute, Ganeshacharya, Singh et al.
Researchers have demonstrated that a specific herbal formulation reduces SARS-CoV-2 viral load by 94.51% in cellular models, whilst accelerating clinical recovery. Quantifying the precise effects of Ayurvedic medicine for COVID-19 has historically proven difficult because complex botanical mixtures resist standard pharmacological testing.
For decades, orthodox medicine has viewed traditional remedies with justifiable scepticism. The old method of assessing these treatments relied heavily on anecdotal evidence or poorly controlled observational data.
Modern virology demands rigorous, quantifiable metrics. Researchers must isolate active compounds, map their binding affinities, and track patient outcomes against standard treatments in blinded conditions.
This new study applied a strict, multi-tiered approach to a traditional herbal blend. The team began with in-silico computational modelling, identifying 20 plant-based compounds that successfully bound to viral targets.
The computational models measured favourable binding affinities against several key viral components:
They then moved to in-vitro testing, where the formulation inhibited viral replication by over 94% within 48 hours. Finally, the investigators ran two clinical trials, including a double-blind, placebo-controlled study with 60 participants.
The clinical measurements were striking. Patients receiving the herbal formulation alongside standard care achieved a 93.3% recovery rate within seven days, reaching 100% by day ten. The data showed distinct reductions in inflammatory markers compared to the control group.
These findings suggest that specific botanical formulations could serve as effective adjuncts to standard antiviral care. By lowering inflammation and aiding immune response, the treatment may shorten hospital stays and reduce symptom severity.
However, a significant gap remains. This study does not solve the issue of standalone efficacy, as all trial participants received the herbal formulation alongside orthodox medical treatments. We still do not know how the formulation performs in isolation.
Furthermore, manufacturing standardisation for complex herbal mixtures remains a formidable hurdle for widespread clinical adoption. Future research must isolate the most potent phyto-compounds to determine exact mechanisms of action. Until then, the formulation remains a promising supplement rather than a primary cure.
Evaluating Ayurvedic medicine for COVID-19
For decades, orthodox medicine has viewed traditional remedies with justifiable scepticism. The old method of assessing these treatments relied heavily on anecdotal evidence or poorly controlled observational data.
Modern virology demands rigorous, quantifiable metrics. Researchers must isolate active compounds, map their binding affinities, and track patient outcomes against standard treatments in blinded conditions.
The Discovery
This new study applied a strict, multi-tiered approach to a traditional herbal blend. The team began with in-silico computational modelling, identifying 20 plant-based compounds that successfully bound to viral targets.
The computational models measured favourable binding affinities against several key viral components:
- Papain-like protease (PLpro)
- RNA-dependent RNA polymerase (RdRp)
- Nucleocapsid (N) proteins
They then moved to in-vitro testing, where the formulation inhibited viral replication by over 94% within 48 hours. Finally, the investigators ran two clinical trials, including a double-blind, placebo-controlled study with 60 participants.
The clinical measurements were striking. Patients receiving the herbal formulation alongside standard care achieved a 93.3% recovery rate within seven days, reaching 100% by day ten. The data showed distinct reductions in inflammatory markers compared to the control group.
The Impact and Unknowns
These findings suggest that specific botanical formulations could serve as effective adjuncts to standard antiviral care. By lowering inflammation and aiding immune response, the treatment may shorten hospital stays and reduce symptom severity.
However, a significant gap remains. This study does not solve the issue of standalone efficacy, as all trial participants received the herbal formulation alongside orthodox medical treatments. We still do not know how the formulation performs in isolation.
Furthermore, manufacturing standardisation for complex herbal mixtures remains a formidable hurdle for widespread clinical adoption. Future research must isolate the most potent phyto-compounds to determine exact mechanisms of action. Until then, the formulation remains a promising supplement rather than a primary cure.
Cite this Article (Harvard Style)
Patsute et al. (2026). 'EXPRESS: Integrating biochemical, computational, and clinical trials to evaluate the efficacy of herbal formulation against SARS-CoV-2.'. Journal of Investigative Medicine. Available at: https://doi.org/10.1177/10815589261429538